TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02199236
Drug: concurrent capecitabine or 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.
Study: NCT02932462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical product
Study: NCT00578474
Drug: Moxidex otic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study: NCT00474500
Drug: Coca, Cola, Diet Coke
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01546428
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01895777
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Study: NCT00309855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: im and orally
Study: NCT00309855
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injections
Study: NCT00223691
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO.Single dose.
Study: NCT00223691
Drug: Ergotamine/ Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
Study: NCT00223691
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-200 mg PO. Single dose
Study: NCT00223691
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25, 50 or 75 mg, PO. Singe dose.
Study: NCT00223691
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300, 600 or 900 mg, PO. Single dose.
Study: NCT00223691
Drug: Carbidopa/levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
Study: NCT00371111
Drug: Intravitreal injection of Avastin
Normalized name: Avastin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 1.25 mg of Avastin and
Study: NCT02395653
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
Study: NCT02495662
Drug: PEG-liposomal prednisolone sodium phosphate
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone phosphate (DB14631)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal prednisolone
Study: NCT02495662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT01832571
Drug: Once daily Truvada®
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
Study: NCT01261611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. injection on day 1 of treatment cycle 1.
Study: NCT03372629
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching ID-085 capsules
Study: NCT03536598
Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03536598
Drug: Valsartan 160 mg + Rosuvastatin 20 mg
Normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03736629
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 weeks of Azithromycin (250 mg) once daily by mouth
Study: NCT03736629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01059396
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo propranolol / carvedilol
Study: NCT02016183
Drug: Candesartan cilexetil / hydrochlorothiazide
Normalized name: candesartan cilexetil / hydrochlorothiazide Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan cilexetil / hydrochlorothiazide combination tablets
Study: NCT01224197
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 200 mg capsule, one single dose
Study: NCT01224197
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 200 mg capsule, once daily for 5 days
Study: NCT00257621
Drug: GW640385
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03006471
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: one per day before breakfast during 12 weeks.
Study: NCT00770328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO TID x 8 weeks
Study: NCT00536133
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
Study: NCT04797338
Drug: Synarel, 0.2 Mg/Inh Nasal Spray
Normalized name: Synarel, 0.2 mg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal treatment with Nafarelin inhaler: 200 micrograms twice daily (a total of 400 micrograms/d; Synarel, Pfizer) on the evening after oocyte retrieval, which will be continued up to the bHCG blood test, 12 days post embryo transfer. In cases with positive serum bHCG results, the treatment will be stopped.
Study: NCT02744534
Drug: FACBC PET-CT Scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist.
Study: NCT03315871
Drug: MSB0011359C (M7824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully human bifunctional fusion protein that combines IgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody. Administered via IV infusion over 1 hour.
Study: NCT01130493
Drug: IPX066
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental product
Study: NCT00902304
Drug: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
Normalized name: valsartan, amlodipine and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
Study: NCT00902304
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: As directed by investigator
Study: NCT00902304
Drug: Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Normalized name: valsartan, amlodipine and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
Study: NCT02220985
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02220985
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04095572
Drug: intravesical instillation with HA-CS
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
Study: NCT03278015
Drug: S-1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
Study: NCT03716856
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion
Study: NCT04196179
Drug: ANG3070
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG-3070 drug product is a an immediate release oral solid. The drug product consists of a Size 00 Swedish orange capsule containing drug substance (10 mg, 50 mg, or 250 mg) with no excipients.
Study: NCT04196179
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANG-3070 placebo capsules visually match the drug product.
Study: NCT01351285
Drug: up-and-down method to find out effective concentration of remifentanil for preventing cough
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
Study: NCT03273296
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
Study: NCT03830151
Drug: Hyperpolarized Carbon C 13 Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01200212
Drug: Taxane, Avastin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Study: NCT01200212
Drug: Taxane, Avastin, Xeloda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
Study: NCT00686166
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy Cycle 1: Capecitabine, 1650 mg/m\^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m\^1, PO, Monday-Friday (Day 50-84)
Study: NCT04360265
Drug: Adjuvant Immunomodulatory (IM) Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive IM therapy.
Study: NCT06758167
Drug: XingpiJieyu formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
Study: NCT06758167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, no therapeutic effect.
Study: NCT01258309
Drug: olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
Study: NCT03051477
Drug: Helixor® M
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hour IV infusion on Monday, Wednesday, and Friday of each week.
Study: NCT01555216
Drug: Single injection posterior tibial nerve block
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of 0.5% ropivacaine
Study: NCT01555216
Drug: Posterior tibial nerve catheter
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
Study: NCT00702988
Drug: recFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recFSH daily (reference group administered under protocol 38826)
Study: NCT00272051
Drug: SR57746A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04063189
Drug: Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
Study: NCT02176551
Drug: Product 0405
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product 0405 will be administered topically twice daily for 28 days.
Study: NCT02176551
Drug: Placebo for Product 0405
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Study: NCT02025881
Drug: Cyclophosphamide + Busilvex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide:~* Level 1 20 mg/kg/day~* Level 2 30 mg/kg/day~* Level 3 40 mg/kg/day~* Level 4 50 mg/kg/day~Busilvex:~\< 9 kgs 0.8 mg/kg/dose -\> 3.2 mg/kg/day; 9 à \< 16 kgs 0.96 mg/kg/dose -\> 3.84 mg/kg/day; 16 à 23 kgs 0.88 mg/kg/dose -\> 3.52 mg/kg/day; \> 23 à 34 kgs 0.76 mg/kg/dose -\> 3.04 mg/kg/day; \> 34 kgs -\> 0.64 mg/kg/dose.
Study: NCT04049175
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of CHF 6532
Study: NCT04049175
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of CHF 6532
Study: NCT01508468
Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
Study: NCT01508468
Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
Study: NCT01512160
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x 200 mg tablets
Study: NCT01912261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule orally daily times 84 days
Study: NCT01912261
Drug: Polysaccharide iron complex
Normalized name: polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg daily orally times 84 days
Study: NCT00408213
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g po bid
Study: NCT00408213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po bid
Study: NCT01108627
Drug: open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
Study: NCT01108627
Drug: foradil placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: open-labeled inhaled corticosteroids (ICS); foradil placebo
Study: NCT02535273
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
Study: NCT02477293
Drug: Hyeonggaeyeongyo-tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03945188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study: NCT01515410
Drug: Sinemet IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
Study: NCT02219048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 680 micrograms BID, Orally inhaled placebo for 12 weeks
Study: NCT04794803
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT04149405
Drug: Bisphosphonate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
Study: NCT01250977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
Study: NCT02871648
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epleronone 100 mg
Study: NCT00439868
Drug: WellbutrinXL
Approvals — FDA: no, EMA: no, PMDA: no
Description: WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
Study: NCT00439868
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets to WELLBUTRIN XL.
Study: NCT01590303
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
Study: NCT01884038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587508
Drug: meloxicam/cyclobenzaprine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: two oral capsules a day during approximately 07 days
Study: NCT01587508
Drug: meloxicam - Movatec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: two oral tablet a day during approximately 07 days
Study: NCT00191607
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02729909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone placebo-matching capsules
Study: NCT00559533
Drug: RO5045337
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
Study: NCT01971047
Drug: Regular Insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose
Study: NCT02660905
Drug: E/C/F/TAF;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Study: NCT01358747
Drug: BEACOPPesc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04052620
Drug: Diclofenac diethylamine 2.32% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Study: NCT04052620
Drug: Diclofenac diethylamine 1.16% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
Study: NCT01321827
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
Study: NCT00329082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5: Placebo QW IV for 12 weeks